Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus RENOGRAFIN 76.
HYPAQUE-M,75% vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent